Frontiers in Oncology · 2020 · 83 citations · 14 references
MedicineCancer BiologyOncologyEpigeneticsGene ExpressionMolecular OncologyCancer BiomarkersCancer TranscriptomicsCervical CancerDna Methylation ProfilingEpigenetic Biomarker DiscoveryEpigenetic BiomarkersCancer Epigenetic BiomarkersDifferential Transcript ExpressionN6-methyladenosine RegulationPrognostic Expression SignaturesPrognostic Gene SignaturesPrognostic PredictionPrognostic Prediction ModelsPrognostic Signature Development
Background: Cervical squamous cell carcinoma (CESC) is one of the most common causes of cancer-related death worldwide. N6-methyladenosine (m6A) plays an important role in various cellular responses by regulating mRNA biology. This study aimed to develop and validate an m6A RNA methylation regulators-based signature for prognostic prediction in CESC. Methods: Clinical and survival data as well as RNA sequencing data of 13 m6A RNA methylation regulators were obtained from The Cancer Genome Atlas (TCGA) CESC database. Consensus clustering was performed to identify different CESC clusters based on the differential expression of the regulators. LASSO Cox regression analysis was used to generate a prognostic signature based on m6A RNA methylation regulators expression. The effect of the signature was further explored by univariate and multivariate Cox analyses. Results: Four regulators (RBM15, METTL3, FTO, and YTHDF2) were identified to be aberrantly expressed in CESC tissues. A prognostic signature includes ZC3H13, YTHDC1 and YTHDF1 was developed, which can act as an independent prognostic indicator. Significant differences of survival rate and clinicopathological features were found between the high- and low-risk groups. The results of bioinformatics analysis were then validated in the clinical CESC cohort by qRT-PCR and immunohistochemistry staining. Conclusion: In the present study, we developed and validated an m6A RNA methylation regulators-based prognostic signature, which might provide useful insights regarding the development and prognosis of CESC.
14
Nuclear m6A Reader YTHDC1 Regulates mRNA Splicing
Wen Xiao, Samir Adhikari, Ujwal Dahal et al. · Molecular Cell · 2016 · 2.1K citations · Full text
Anti-tumour immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells
Dali Han, Jun Liu, Chuanyuan Chen et al. · Nature · 2019 · 990 citations
Medicine, Immunology, Oncology +12
Zc3h13 Regulates Nuclear RNA m6A Methylation and Mouse Embryonic Stem Cell Self-Renewal
Jing Wen, Ruitu Lv, Honghui Ma et al. · Molecular Cell · 2018 · 990 citations · Full text